|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
CDER?s Division of Post-Marketing Evaluation for Quality Assessment
The new Division of Post Marketing Evaluation in the Office of New Drug Quality Assessment has implemented an improved system for managing the submission and review processes for post approval chemistry, manufacturing, and controls change supplements.
Advertisement
Articles in this issue
over 19 years ago
Analytical Instrument Qualificationover 19 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?over 19 years ago
Team Effortover 19 years ago
Rated PG: Pharmaceutical Guidance Suggestedover 19 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionover 19 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressover 19 years ago
New Climateover 19 years ago
2006: A Regulatory OdysseyNewsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
